1. Mepolizumab, targeting IL-5, reduced COPD exacerbation frequency and emergency visits/hospitalizations.
2. Study included 804 COPD patients with elevated eosinophil levels.
3. Participants receiving mepolizumab showed a 21% relative reduction in exacerbation rate.
4. Time to first exacerbation was longer with mepolizumab.
5. No significant differences in patient-reported outcomes were observed.
6. Adverse events were reported in 74% of the mepolizumab group and 77% of the placebo group.
7. Common adverse events with mepolizumab included worsening COPD and SARS-CoV-2 infection.

Source: The New England Journal of Medicine